Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Dec;49(12):2298-307.
doi: 10.1080/10428190802517732.

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia

Julie E Chang  1 , Stephen C Medlin, Brad S Kahl, Walter L Longo, Eliot C Williams, Jack Lionberger, Kyungmann Kim, Jihoon Kim, Elizabeth Esterberg, Mark B Juckett
Affiliations
Clinical Trial

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia

Julie E Chang et al. Leuk Lymphoma. 2008 Dec.

Abstract

The augmented Berlin-Frankfurt-Munster (aBFM) regimen has demonstrated improved outcomes in children with acute lymphomblastic leukemia (ALL), but efficacy in adults is unknown. In this retrospective study, we evaluated clinical outcomes in 29 adult ALL patients (aged 19-70) treated with standard BFM (sBFM) or dose-intensive aBFM. Patients were stratified into risk groups based on age, cytogenetic abnormalities, peripheral leukocytosis and response to induction chemotherapy. Inter-mediate risk patients less than 50 years old and all high-risk patients were assigned to aBFM. Complete remission after induction therapy was achieved in 93% of patients. Fifteen patients completed a full course of BFM chemotherapy, with seven discontinuing because of relapse, three because of toxicity, two because of transplantation and two toxic deaths. Five-year event-free survival (EFS) was 45% (95% CI 30-67%), with 39% and 50% rates of EFS observed in the aBFM and sBFM subgroups at 5 years, respectively. Overall survival at 5 years was 62% (95% CI 46-82%), with 61% and 62% in the aBFM and sBFM subgroups alive at 5 years, respectively. Two toxic deaths were observed, and infections and neuropathy were the most common toxicities. sBFM and aBFM have efficacy and toxicity comparable with other adult ALL regimens.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Kaplan-Meier plots of event-free survival (n=29).
Figure 2
Figure 2
Kaplan-Meier plots of overall survival (n=29).
See this image and copyright information in PMC

References

    1. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995;85:1151–1168. - PubMed
    1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548. - PubMed
    1. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997;24:70–82. - PubMed
    1. Riehm H, Gadner H, Henze G, Kornhuber B, Langermann HJ, Müller-Weihrich S, et al. Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–81) In: Murphy SB, Gilbert JR, editors. Leukemia Research: Advances in Cell Biology and Treatment. New York: Elsevier Science Publishing; 1983. pp. 251–263.
    1. Riehm H, Langermann HJ, Gadner H, Odenwald E, Henze G. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976. Am J Ped Hematol Oncol. 1980;2:299–306.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources